(DOCS) Doximity - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 3.686m USD | Total Return: -62.5% in 12m
Telehealth, Medical Networking, Digital Recruitment, Workflow Tools
Total Rating 37
Safety 88
Buy Signal -0.37
Health Information Services
Industry Rotation: -12.0
Industry Rotation: -12.0
Market Cap:
3.69B
Avg Turnover: 78.3M
Avg Turnover: 78.3M
Risk 3d forecast
Volatility62.7%
VaR 5th Pctl8.80%
VaR vs Median-22.3%
Reward TTM
Sharpe Ratio-1.62
Rel. Str. IBD0.6
Rel. Str. Peer Group10
Character TTM
Beta1.760
Beta Downside1.560
Hurst Exponent0.621
Drawdowns 3y
Max DD78.34%
CAGR/Max DD-0.18
CAGR/Mean DD-0.51
EPS (Earnings per Share)
EPS CAGR: 17.95%
EPS Trend: 85.0%
EPS Trend: 85.0%
Last SUE: -0.58
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 13.43%
Rev. Trend: 89.9%
Rev. Trend: 89.9%
Last SUE: 0.26
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: DOCS Doximity
Doximity, Inc. (NYSE: DOCS) operates a professional digital network specifically designed for medical practitioners in the United States. The platform integrates communication tools, career management features, and clinical workflow solutions, including virtual patient visits and electronic documentation. Its membership base includes physicians, nurse practitioners, and physician assistants, while its primary revenue streams come from pharmaceutical companies and healthcare systems seeking targeted marketing and recruitment solutions.
The company functions within the Health Care Technology sector, utilizing a software-as-a-service (SaaS) model to digitize traditionally manual administrative tasks. By centralizing medical news and on-call scheduling, the platform aims to reduce physician burnout and improve clinical efficiency. Investors may find ValueRays detailed metrics useful for further evaluating the companys valuation.
Founded in 2010 and headquartered in San Francisco, Doximity has established a significant market presence by creating a verified network that limits access to credentialed professionals. This walled-garden approach allows the company to maintain high data integrity for its enterprise clients in the highly regulated healthcare industry.
- Pharmaceutical marketing budget shifts toward digital platforms drive core advertising revenue
- High physician engagement levels maintain pricing power with hospital system clients
- Telehealth adoption rates and usage volume influence recurring subscription service growth
- Expansion of AI-powered clinical documentation tools impacts long-term software margin expansion
- Regulatory changes to healthcare data privacy standards pose potential operational compliance risks
Piotroski VR‑10 (Strict)
7.0
| Net Income: 196.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.29 > 0.02 and ΔFCF/TA 7.74 > 1.0 |
| NWC/Revenue: 122.4% < 20% (prev 163.5%; Δ -41.06% < -1%) |
| CFO/TA 0.29 > 3% & CFO 326.5m > Net Income 196.1m |
| Net Debt (-738.4m) to EBITDA (245.8m): -3.00 < 3 |
| Current Ratio: 6.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.0m) vs 12m ago -3.92% < -2% |
| Gross Margin: 89.09% > 18% (prev 0.90%; Δ 8.82k% > 0.5%) |
| Asset Turnover: 54.01% > 50% (prev 45.12%; Δ 8.89% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z''
5.33
| A: 0.70 (Total Current Assets 944.3m - Total Current Liabilities 155.0m) / Total Assets 1.12b |
| B: -0.05 (Retained Earnings -51.1m / Total Assets 1.12b) |
| C: 0.18 (EBIT TTM 209.0m / Avg Total Assets 1.19b) |
| D: -0.29 (Book Value of Equity -50.9m / Total Liabilities 172.8m) |
| Altman-Z'' Score: 5.33 = AAA |
Beneish M
-2.96
| DSRI: 1.00 (Receivables 144.8m/128.4m, Revenue 644.9m/570.4m) |
| GMI: 1.01 (GM 89.09% / 90.20%) |
| AQI: 1.13 (AQ_t 0.14 / AQ_t-1 0.12) |
| SGI: 1.13 (Revenue 644.9m / 570.4m) |
| TATA: -0.12 (NI 196.1m - CFO 326.5m) / TA 1.12b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of DOCS shares?
As of May 21, 2026, the stock is trading at USD 19.86 with a total of 4,496,101 shares traded.
Over the past week, the price has changed by -15.09%, over one month by -18.57%, over three months by -22.27% and over the past year by -62.53%.
Over the past week, the price has changed by -15.09%, over one month by -18.57%, over three months by -22.27% and over the past year by -62.53%.
Is DOCS a buy, sell or hold?
Doximity has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold DOCS.
- StrongBuy: 5
- Buy: 3
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOCS price?
| Analysts Target Price | 25.2 | 26.6% |
Doximity (DOCS) - Fundamental Data Overview
as of 20 May 2026
P/E Trailing = 19.9796 P/E Forward = 13.6986
P/S = 5.7165
P/B = 3.8036
P/EG = 0.5953
Revenue TTM = 644.9m USD
EBIT TTM = 209.0m USD
EBITDA TTM = 245.8m USD
Long Term Debt = 8.07m USD (estimated: total debt 10.2m - short term 2.11m)
Short Term Debt = 2.11m USD (from shortTermDebt, last quarter)
Debt = 10.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -738.4m USD (recalculated: Debt 10.2m - CCE 748.6m)
Enterprise Value = 2.95b USD (3.69b + Debt 10.2m - CCE 748.6m)
Interest Coverage Ratio = unknown (Ebit TTM 209.0m / Interest Expense TTM 0.0)
EV/FCF = 9.10x (Enterprise Value 2.95b / FCF TTM 324.1m)
FCF Yield = 10.99% (FCF TTM 324.1m / Enterprise Value 2.95b)
FCF Margin = 50.26% (FCF TTM 324.1m / Revenue TTM 644.9m)
Net Margin = 30.40% (Net Income TTM 196.1m / Revenue TTM 644.9m)
Gross Margin = 89.09% ((Revenue TTM 644.9m - Cost of Revenue TTM 70.3m) / Revenue TTM)
Gross Margin QoQ = 86.65% (prev 89.89%)
Tobins Q-Ratio = 2.62 (Enterprise Value 2.95b / Total Assets 1.12b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.2m)
Taxrate = 40.49% (13.0m / 32.1m)
NOPAT = 124.4m (EBIT 209.0m * (1 - 40.49%))
Current Ratio = 6.09 (Total Current Assets 944.3m / Total Current Liabilities 155.0m)
Debt / Equity = 0.01 (Debt 10.2m / totalStockholderEquity, last quarter 950.8m)
Debt / EBITDA = -3.00 (Net Debt -738.4m / EBITDA 245.8m)
Debt / FCF = -2.28 (Net Debt -738.4m / FCF TTM 324.1m)
Total Stockholder Equity = 1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.42% (Net Income 196.1m / Total Assets 1.12b)
RoE = 19.36% (Net Income TTM 196.1m / Total Stockholder Equity 1.01b)
RoCE = 20.47% (EBIT 209.0m / Capital Employed (Equity 1.01b + L.T.Debt 8.07m))
RoIC = 12.03% (NOPAT 124.4m / Invested Capital 1.03b)
WACC = 12.14% (E(3.69b)/V(3.70b) * Re(12.17%) + D(10.2m)/V(3.70b) * Rd(0.0%) * (1-Tc(0.40)))
Discount Rate = 12.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -17.98 | Cagr: -1.21%
[DCF] Terminal Value 69.29% ; FCFF base≈301.1m ; Y1≈371.5m ; Y5≈633.9m
[DCF] Fair Price = 48.99 (EV 5.82b - Net Debt -738.4m = Equity 6.56b / Shares 133.8m; r=12.14% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 85.02 | EPS CAGR: 17.95% | SUE: -0.58 | # QB: 0
Revenue Correlation: 89.94 | Revenue CAGR: 13.43% | SUE: 0.26 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.30 | Chg30d=-12.45% | Revisions=-76% | Analysts=19
EPS next Quarter (2026-09-30): EPS=0.37 | Chg30d=-12.40% | Revisions=-20% | Analysts=19
EPS current Year (2027-03-31): EPS=1.43 | Chg30d=-11.61% | Revisions=-75% | GrowthEPS=-5.7% | GrowthRev=+4.0%
EPS next Year (2028-03-31): EPS=1.59 | Chg30d=-11.09% | Revisions=-67% | GrowthEPS=+11.3% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: -76%